Will ‘Vemlidy’ become a new power in chronic hepatitis B treatment market?
Pharmaceutical companies have been highly competitive to develop new chronic hepatitis B treatments. In the competition, Gilead developed a new drug called ‘Vemlidy(generic name: tenofovir alafenamide, aka. TAF)’ and acquired approvals last November from the FDA and on the 16th in Korea.
This is...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
